• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MannKind Corporation - Common Stock (NQ:MNKD)

    3.880 +0.040 (+1.04%)
    Streaming Delayed Price Updated: 2:20 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,649,264
    Open 3.860
    Bid (Size) 3.870 (6,800)
    Ask (Size) 3.880 (1,500)
    Prev. Close 3.840
    Today's Range 3.835 - 3.920
    52wk Range 2.230 - 6.510
    Shares Outstanding 264,305,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MannKind Q2 Earnings Call Highlights ↗
    MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased... 
    Via MarketBeat
    Topics Earnings
    MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue ↗
    Via Chartmill

    Performance

    YTD
    -30.7%
    -30.7%
    1 Month
    -4.0%
    -4.0%
    3 Month
    +18.3%
    +18.3%
    6 Month
    -33.4%
    -33.4%
    1 Year
    +13.5%
    +13.5%

    More News

    Read More
    News headline image
    MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway ↗
    Via MarketBeat
    News headline image
    MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
    From MannKind
    Via GlobeNewswire
    MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress ↗
    Via Chartmill
    News headline image
    MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE ↗
    Via MarketBeat
    News headline image
    MannKind Announces $50 Million Private Placement
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
    From MannKind
    Via GlobeNewswire
    News headline image
    What This MannKind Filing Reveals About Three Years of Underperformance ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
    From MannKind
    Via GlobeNewswire
    News headline image
    Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗
    Via MarketBeat
    News headline image
    MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Present at Jefferies Global Healthcare Conference
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind (MNKD) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
    From MannKind
    Via GlobeNewswire

    Frequently Asked Questions

    Is MannKind Corporation - Common Stock publicly traded?
    Yes, MannKind Corporation - Common Stock is publicly traded.
    What exchange does MannKind Corporation - Common Stock trade on?
    MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MannKind Corporation - Common Stock?
    The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
    What is the current price of MannKind Corporation - Common Stock?
    The current price of MannKind Corporation - Common Stock is 3.880
    When was MannKind Corporation - Common Stock last traded?
    The last trade of MannKind Corporation - Common Stock was at 08/12/26 02:20 PM ET
    What is the market capitalization of MannKind Corporation - Common Stock?
    The market capitalization of MannKind Corporation - Common Stock is 1.03B
    How many shares of MannKind Corporation - Common Stock are outstanding?
    MannKind Corporation - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.